Adam Schoenfeld, MD
Gastroenterology · New Britain, CTNPI 1902080278
Payments from drug & device makers
Across 316 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$662
- Johnson & Johnson$586
- Iovance Biotherapeutics, Inc.$406
- Pfizer$308
- plus $2K from 23 others
What the payments were for
- Consulting fees$200%
- Travel & lodging$2293%
- Food & beverage$6,46395%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,621 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $1,005 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $662 |
| Johnson & Johnson(2 entities) | 28 | $586 |
| Iovance Biotherapeutics, Inc. | 5 | $406 |
| Pfizer | 23 | $308 |
| Regeneron Healthcare Solutions, Inc. | 11 | $251 |
| Gilead | 7 | $246 |
| Madrigal Pharmaceuticals | 4 | $235 |
| Intercept Pharmaceuticals, Inc. | 8 | $192 |
| Sanofi | 7 | $168 |
| Bristol Myers Squibb | 9 | $166 |
| Ardelyx, Inc. | 7 | $149 |
| Lilly USA, LLC | 6 | $133 |
| Phathom Pharmaceuticals, Inc. | 9 | $114 |
| Ironwood Pharmaceuticals, Inc | 6 | $112 |
| Ferring Pharmaceuticals Inc. | 5 | $97 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| QOL Medical, LLC | 2 | $38 |
| Celltrion USA Inc. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| Braintree Laboratories, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Evoke Pharma, Inc. | 2 | $27 |
| Novo Nordisk | 1 | $23 |
| Digestive Care, Inc. | 1 | $22 |
| Gastrogpo, LLC | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,791 in reported general payments places this provider in the 65th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $454,044 |
| LinzessLinaclotide | 55 | $73,030 |
| CreonLipase/Protease/Amylase | 11 | $37,957 |
| MotegrityPrucalopride Succinate | 30 | $30,640 |
| Mesalamine | 42 | $19,997 |
| NexiumEsomeprazole Magnesium | 11 | $10,349 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 171 | $10,154 |
| Lubiprostone | 37 | $8,601 |
| Dexlansoprazole DrDexlansoprazole | 16 | $7,573 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 45 | $7,389 |
| MovantikNaloxegol Oxalate | 11 | $5,507 |
| Famotidine | 200 | $4,247 |
| Omeprazole | 263 | $4,151 |
| Pantoprazole Sodium | 151 | $2,139 |
| Budesonide EcBudesonide | 11 | $1,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $586 | $454,04417 claims |
| AbbVieLinzess, Creon | $1,621 | $110,98766 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,005 | $30,64030 claims |
| Braintree Laboratories, Inc.Sutab | $31 | $7,38945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in New Britain
- Pramod MistryNew Haven$6M
- Salam ZakkoBristol$2.7M
- Paul FeuerstadtHamden$1.4M
- Angelo ParedesMiddletown$1.3M
- James FrestonFarmington$778K
- Jill GaidosNew Haven$750K
- Houman RezaizadehFarmington$720K
- James BoyerNew Haven$648K
- Guadalupe Garcia TsaoNew Haven$555K
- Loren LaineWest Haven$485K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.